Fulgent Genetics (FLGT) Projected to Post Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is anticipated to issue its quarterly earnings data before the market opens on Friday, February 28th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $75.39 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Fulgent Genetics Stock Down 2.7 %

FLGT stock opened at $16.29 on Wednesday. The business’s fifty day moving average is $17.55 and its 200-day moving average is $19.66. The company has a market cap of $498.35 million, a P/E ratio of -2.95 and a beta of 1.39. Fulgent Genetics has a twelve month low of $15.99 and a twelve month high of $25.50.

Wall Street Analyst Weigh In

A number of research firms recently commented on FLGT. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. Piper Sandler reduced their price objective on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.